Ercros SA

07/07/2021 | Press release | Distributed by Public on 07/07/2021 04:33

Ercros will invest more than 20 million in Aranjuez until 2025

Aranjuez, July 7, 2021. - Ercros plans to invest 20 million euros in its factory in Aranjuez (Madrid), 16 million of which in 10 actions planned in the 3D Plan.

The 3D Plan is the strategic plan started up by Ercros, which pursues its transformation into a sustainable company and is based on three dimensions: Diversification, Digitalisation and Decarbonisation. This plan contains 20 major projects, 10 of which will be carried out in Aranjuez. The timeframe of the plan is the period 2021-2025, although the execution of several digitalisation and decarbonisation projects will go beyond this period and will extend until 2029.

For the period 2021-2029, Ercros foresees for the entire company an investment of 92 million euros and the generation of an additional gross operating profit (ebitda) of 194 million euros.

The 16 million to be invested in Aranjuez under the 3D Plan are distributed as follows:

  • 77.5% in a major diversification project: the construction of a new extraction plant for the production of two new antibiotics;
  • 15.5% in six digitalisation projects; and
  • The remaining 7% in three decarbonisation projects.

Carrying out the 10 actions will reinforce the sustainability of the Ercros project in Aranjuez, by promoting the diversification of the activity, increasing the automation and digitalisation of the processes and improving the environmental performance of the facilities.

In the last 14 years (2007-2020), Ercros has invested more than 32 million euros in the Aranjuez factory.

The 3D Plan succeeds the Plan Act (2016-2020), for adaptation to technological change, which involved the modernization of Ercros's production structure and the incorporation of important energy efficiency improvements.

The Ercros factory in Aranjuez makes up the pharmaceuticals division. This centre is designed to manufacture active pharmaceutical ingredients (API), mainly from the family of antibiotics. The factory directly employs 211 persons and in 2020 had a turnover of 58 million euros. 92% of its sales went to export, mainly to the US, the EU, the Middle East and North Africa.